Treatment of naive patients with chronic hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 168-173

  Weiland, Ola ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alpha interferon; Anti viral therapy; Chronic hepatitis; Hepatitis C; Hepatitis C virus RNA; Ribavirin

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS C; HUMAN; INSOMNIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MENTAL DISEASE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; VIRUS LOAD;

EID: 0033405929     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80395-x     Document Type: Conference Paper

References (20)

1. Statement P. Management of hepatitis C: NIH consensus development conference panel statement. Hepatology 1997: 26 (Suppl 1): 2S-10S.
2. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997: 26 (Suppl 1): 108S-111S.
3. Davis G, Esteban, Muir R, Rustgi V et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998: 339: 1493-1499.
4. Hultgren C, Milich D, Weiland O, Sällberg M. The antiviral compound ribavirin modulates the T helper (Th)l/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998: 79: 2381-2391.
5. Poynard T, Marcellin P, Lee S et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 14261432.
6. McHutchison J, Gordon S, Schiff E et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
7. Schalm S, Hansen B, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: a meta-analysis of individual patient data from European centers. J Hepatol 1997: 26: 961-966.
8. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Albert! A. The effect of interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995: 23 (Suppl 2): 8-12.
9. Braconier J, Paulsen O, Engman K, Widell A. Combined alphainterferon and ribavirin treatment for chronic hepatitis C virus infection. Scand J Infect Dis 1995: 27: 325-329.
10. Kakumu S, Yoshioko K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993: 105: 507-512.
11. Lai M-Y, Kao J-H, Yang P-M et al. Long-term efficacy of ribavirin plus Interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996: 111: 1307-1312.
12. Reichard O, Norkrans G, Frydén A, Braconier J, Sônnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998: 351: 83-87.
13. Marcellin P, Boyer N, Gervais A et al. Long-term histologie improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997: 127: 875-881.
14. Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstâl R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999: 30: 783-787.
15. Schalm S, Weiland O, Hansen B et al. and the EUROHEP Study Group for Viral Hepatitis. Interferon/ribavirin treatment for chronic hepatitis C with and without cirrhosis: a meta-analysis of individual patient data. Gastroenterology, in press.
16. Weiland O, Braconier J, Frydén A et al. Influence of pretreatment factors on outcome of Interferon alpha treatment in patients with chronic hepatitis C infection. Scand J Infect Dis 1999: 31: 115118.
17. Brouwer J, Hansen B, Niesters H, Schalm S. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999: 30: 192-198.
18. Poynard T. Interferon alpha for chronic hepatitis C infection Correspondence - Author's reply. Lancet 1999: 353: 499-500.
19. Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon alpha-2b and ribavirin for chronic hepatitis C. J Viral Hepatitis 1999: 6: 237-242.
20. Neumann A, Lam N, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998: 282: 103-107.